Products for Research Use Only
RegisterLogin

Runcaciguat

CAT: 0804-HY-109136-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109136-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) [1][2][3].
CAS Number
1402936-61-1
Product Name Alternative
BAY 1101042
UNSPSC
12352005
Hazard Statement
H302
Target
Guanylate Cyclase
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/runcaciguat.html
Purity
99.31
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC([C@H](C2CC2)CC(O)=O)=CC=C1Cl)[C@@](C3=CC=C(Cl)C=C3)([H])[C@@H](C)C(F)(F)F
Molecular Formula
C23H22Cl2F3NO3
Molecular Weight
488.33
Precautions
H302
References & Citations
[1]Wittrien T, et al. Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation. Biochem Pharmacol. 2025 Feb;232:116739.|[2]Bénardeau A, et al. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394 (12) :2363-2379.|[3]Kraehling JR, et al. The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats. Int J Mol Sci. 2023 Aug 25;24 (17) :13226.|[4]Duh EJ, et al. Neuroprotective Effect of a Novel Soluble Guanylate Cyclase Activator (sGCa) Runcaciguat in Diabetes and Ischemic Retinopathy. Diabetes. 2025 Apr 18:db240739.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
BA5388-50Runcaciguat
A20200-50Runcaciguat 50mg
A20200-25Runcaciguat 25mg
A20200-1Runcaciguat 1mg
A20200-100Runcaciguat 100mg
A20200-10Runcaciguat 10mg
A20200-5Runcaciguat 5mg
A20200-10mM-DRuncaciguat 10mM * 1mL in DMSO

Popular Products